The Asia Pacific Immunotherapy Drugs Market was valued at $61500 Million in 2024 and projected to reach to $127400 Million by 2029, representing a compound annual growth rate of 15.7%. The Asia Pacific immunotherapy drugs market is positioned for exceptional growth through 2029, driven by demographic shifts, rising cancer burden, and substantial healthcare modernization initiatives across the region.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Asia Pacific immunotherapy drugs market valued at $61.5 billion in 2024, projected to reach $127.4 billion by 2029, representing a 15.7% CAGR—outpacing the global average of 15.3%.
Escalating cancer prevalence across Asia Pacific nations is driving demand for advanced immunotherapy treatments, with increasing patient populations requiring targeted therapeutic interventions.
Substantial increases in healthcare infrastructure spending and pharmaceutical R&D investments across Asia Pacific countries are accelerating immunotherapy drug development and market penetration.
Growing adoption of immunotherapy treatments in Asia Pacific is supported by improved healthcare accessibility, regulatory approvals, and expanding reimbursement policies in key markets.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | OTHER IMMUNOTHERAPY DRUGS (Type) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 15.3% from 2024 to 2029 |
| Largest Segment | HOSPITALS (End User) |
| Market Size Base Year (Billions) | ~USD 284.92 (2024) |
| Revenue Forecast (Billions) | ~USD 580.6 (2029) |
| Segments Covered | Type, Application, Route Of Administration, End User |
4 segment dimensions are covered across the global market.
| Country | 2025 size (native) |
|---|---|
| China | USD 21100 Million |
| Japan | USD 28000 Million |
| India | USD 11500 Million |
| South Korea | USD 6900 Million |
| Australia | USD 7200 Million |
| Rest Of Asia Pacific | USD 8200 Million |
The Asia Pacific immunotherapy drugs market was valued at $61.5 billion in 2024 and is projected to reach $127.4 billion by 2029.
Asia Pacific's immunotherapy drugs market is growing at a compound annual growth rate (CAGR) of 15.7% from 2024 to 2029.
Major markets in Asia Pacific include China, Japan, South Korea, and India, which collectively represent the largest share of regional immunotherapy drug demand.
Key drivers include rising cancer incidence, improving healthcare infrastructure, expanding regulatory approvals, increasing disposable incomes, and growing pharmaceutical investments in the region.
Asia Pacific's 15.7% CAGR slightly exceeds the global average of 15.3%, positioning the region as a faster-growing market for immunotherapy drugs.
This study involved four major activities in estimating the current size of the immunotherapy drugs market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the immunotherapy drugs market. The secondary sources referred to for this research study include publications from government sources, such as National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), World Health Organization (WHO), European Pharmaceutical Review, American Society of Gene & Cell Therapy (ASGCT), European Society of Gene and Cell Therapy (ESGCT), European Medicines Agency (EMA), and the Alliance for Regenerative Medicine (ARM). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the immunotherapy drugs market, which was validated through primary research. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

To know about the assumptions considered for the study, download the pdf brochure
The global size of the immunotherapy drugs market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the immunotherapy drugs and other dependent submarkets. The research methodology used to estimate the market size includes the following:

To know about the assumptions considered for the study, Request for Free Sample Report
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the immunotherapy drugs market.
Immunotherapy drugs are a broad category of therapeutic agents that help stimulate the body's immune system to combat diseases. These drugs include antibody therapies, cell & gene therapy, inhibitor drugs, and other drugs such as oncolytic viral therapy and cancer vaccines. These drugs are engineered to enhance the immune response or counteract the immune system's regulatory mechanisms, thereby enabling the body to effectively target and eliminate disease-causing agents or cells. Immunotherapy drugs are used to treat various medical conditions, including cancer, autoimmune diseases, hematology, osteology, neurology, and other therapy areas (such as ophthalmology, dermatology, and cardiovascular disorders).
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Full forecast, segment splits, and company analysis for all Immunotherapy Drugs Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report